Drugplain

Rybrevant Faspro 3520 mg/22mL

AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) · INJECTION · Janssen Biotech, Inc.

No Recall History
Plain English

Rybrevant Faspro is a injection containing amivantamab and hyaluronidase-lpuj (human recombinant) at 3520 mg/22mL, taken subcutaneous. Manufactured by Janssen Biotech, Inc..

Key Facts

Brand Name
Rybrevant Faspro
Generic Name
AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT)
NDC Code (Product)
57894-522
Manufacturer
Janssen Biotech, Inc.
Strength
3520 mg/22mL
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Marketing Status
Application #
BLA761484
Drug Class
Endoglycosidase [EPC]
Marketing Start
02/13/2026

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

administration related reaction6 reports
chills3 reports
myalgia3 reports
rash3 reports
embolism venous2 reports
injection site reaction2 reports
ascites1 reports
blister1 reports
blood pressure decreased1 reports
chest pain1 reports

Frequently Asked Questions

What is Rybrevant Faspro used for?

Rybrevant Faspro contains AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT). It is a injection taken subcutaneous. Consult your doctor for specific uses.

Is Rybrevant Faspro a controlled substance?

Rybrevant Faspro is not classified as a controlled substance by the DEA.

What is the generic name for Rybrevant Faspro?

The generic name for Rybrevant Faspro is AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT). There are no other listed brand versions of AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT).

What is the NDC code for Rybrevant Faspro 3520 mg/22mL?

The NDC (National Drug Code) for Rybrevant Faspro 3520 mg/22mL is 57894-522, listed by Janssen Biotech, Inc..

Product NDC

57894-522

Package NDC

57894-522-01

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)